The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...
Careers today are being lived at an intensity, surely not designed for endurance. This mismatch between career length and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback